FDA adds boxed warning to Elevidys for acute liver injury; non-ambulatory indication removed

Sarepta Therapeutics/Elevidys

Following reports of fatal acute liver failure in non-ambulatory pediatric patients, the FDA required a boxed warning for serious liver injury and liver failure, and removed the non-ambulatory indication. The label now mandates weekly liver tests for three months post-infusion.